EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine

Xiaohua Wang, Yindi Cheng, Jiahui Huang, Feixuan Xu, Jian Jiang, Nonthaneth Nalinratana, Litong Jin, Ying Xue

Frontiers in Microbiology · 20.01.2026 · 16

DOI: 10.3389/fmicb.2025.1696524 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 20.01.2026. Verfasst von Xiaohua Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory for Restoration of Damaged Coastal Ecosystems, Zhejiang International Science and Technology Cooperation Base for Biomass Res…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agricultural Science and Technology Program in Taizhou, Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project, “Pioneer” and “Leading Goose” R&D Program of Zhej.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is a prevalent chronic gastrointestinal disorder. Conventional therapies are often limited by adverse effects and suboptimal long-term efficacy. Probiotics have emerged as promising therapeutic alternatives for IBD because of their ability to modulate the gut microbiota, reinforce intestinal barrier integrity, and regulate immune responses. However, their clinical translation is hampered by challenges within the harsh gastrointestinal milieu, including low viability, poor colonization, and insufficient target specificity. This review focuses on the engineering of probiotics designed to overcome these limitations for IBD management. We outline the therapeutic potential and mechanisms of action of probiotics in IBD, with a critical emphasis on discrepancies between preclinical and clinical observations. We subsequently discuss the drawbacks of conventional probiotic therapies, highlighting gaps between in vitro efficacy and in vivo performance. We then highlight cutting-edge engineering strategies, encompassing advanced encapsulation techniques, genetic engineering approaches, novel delivery systems, and molecular-targeting modifications, with quantitative comparisons of their advantages, limitations, and translational potential. The application of these engineered probiotics specifically in UC and CD treatment is explored, with detailed analyses of preclinical models and clinical trials. We also address personalized interventions tailored to individual gut microbiome profiles. Despite significant promise, critical challenges remain, including long-term safety, stability, and accurate prediction of therapeutic responses for engineered probiotics in IBD. Nevertheless, with ongoing advancements in gene editing, synthetic biology, and microbial safety engineering, engineered probiotics represent a promising direction in IBD therapy that will enable more precise, effective, and personalized treatment modalities, provided that safety, reproducibility, and regulatory compliance are prioritized.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasebiosafetyengineered probioticsgenetic engineeringgut microbiomeinflammatory bowel diseaseprecision medicineulcerative colitis

Autor:innen und Institutionen

  • Zhejiang Key Laboratory for Restoration of Damaged Coastal Ecosystems, Zhejiang International Science and Technology Cooperation Base for Biomass Resources Development and Utilization, Taizhou Key Laboratory of Biomedic…
  • Department of Emergency Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
  • Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University, Bangkok, Thailand.

Förderung

  • Agricultural Science and Technology Program in Taizhou
  • Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project
  • “Pioneer” and “Leading Goose” R&D Program of Zhej
  • National Natural Science Foundation of China

Zitieren

APA

Wang, X., Cheng, Y., Huang, J., Xu, F., Jiang, J., Nalinratana, N., Jin, L., & Xue, Y. (2026). Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1696524

Vancouver

Wang X, Cheng Y, Huang J, Xu F, Jiang J, Nalinratana N, et al. Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine. Frontiers in Microbiology. 2026;16. doi:10.3389/fmicb.2025.1696524

BibTeX
@article{Wang2026,
  author = {Wang, Xiaohua and Cheng, Yindi and Huang, Jiahui and Xu, Feixuan and Jiang, Jian and Nalinratana, Nonthaneth and Jin, Litong and Xue, Ying},
  title = {Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fmicb.2025.1696524}
}
Kostenlos starten →